Blue Bell, Pennsylvania (BUSINESS WIRE) — Mitochon Pharmaceuticals today announced that they, in partnership with the University of Kentucky (UK) and Children’s Hospital of Philadelphia (CHOP), were awarded a $3.2M National Institutes of Health grant to study Mitochon’s mitochondrial targeted drug therapies for treating Traumatic Brain Injury (TBI). This important award, along with the Company’s open IND, will help pave the way for new potential therapies for treating the devastating effects of brain trauma.
“We are delighted to receive this grant. Traumatic Brain Injury affects the daily lives of millions of people with no treatments to curb the devastating effects post-trauma for both civilians and military.” – commented Dr. John Geisler, Ph.D., Mitochon’s Chief Scientific Officer. Mitochon’s compound MP-201, has previously been shown by TBI expert Dr. Patrick Sullivan, Ph.D. at the UK to significantly reduce brain volume loss and restore cognition after two weeks of treatment post injury. The $3.2M award was made to Dr. Patrick Sullivan at UK and Dr. Todd Kilbaugh, M.D. at the CHOP to conduct more advanced studies with MP-201 in models of TBI.
MP-101 and MP-201 are mitochondrial targeted, once-a-day oral therapies that have been shown to shield cells from damage caused by a host of degenerative processes (genetic, non-genetic, auto-immune and injury). In preclinical studies, these compounds have exhibited protective and functional benefits in disease models. These include brain volume sparing in Huntington’s Disease, preserving dopamine neurons in Parkinson’s Disease, and sustaining motor skills in Amyotrophic Lateral Sclerosis (ALS).
Read full press release here.